How Immunotherapy Works Against Mesothelioma
Immunotherapy, also called biologic therapy, helps the body's immune system fight cancer. Unlike chemotherapy, which directly attacks cancer cells, immunotherapy empowers the body's natural defenses to recognize and destroy malignant cells.
The Immune System and Cancer
Normally, the immune system detects and eliminates abnormal cells, including cancer cells. However, mesothelioma cells can evade immune detection by:
- Producing proteins that inhibit immune cell function
- Appearing similar to normal cells, avoiding recognition
- Creating an immunosuppressive environment around tumors
- Expressing checkpoint molecules that turn off immune responses
How Immunotherapy Helps
Immunotherapy drugs work through several mechanisms by leveraging your immune system's ability to recognize and fight cancer:
- Checkpoint inhibition: Blocks proteins that stop immune cells from attacking cancer
- Immune activation: Stimulates immune cells to recognize tumor antigens
- Tumor exposure: Makes cancer cells more visible to the immune system
- Memory response: Creates long-term immunity against cancer recurrence
Advantages Over Traditional Treatment
- Can produce durable, long-lasting responses
- Different side effect profile than chemotherapy
- May work when other treatments fail
- Potential for continued benefit after treatment ends
- Can be combined with other therapies
Checkpoint Inhibitors for Mesothelioma
Checkpoint inhibitors are the most widely used immunotherapy drugs for mesothelioma. They block specific proteins that prevent T-cells from attacking cancer cells.
PD-1/PD-L1 Pathway
The PD-1 (Programmed Cell Death Protein 1) pathway is a key target in mesothelioma immunotherapy:
- PD-1: Protein on T-cells that acts as an "off switch"
- PD-L1: Protein expressed by some cancer cells that binds to PD-1
- The interaction: When PD-L1 binds PD-1, T-cells stop attacking
- Inhibition: Blocking this interaction allows T-cells to attack cancer
CTLA-4 Pathway
CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4) is another checkpoint protein:
- Acts as an immune system "brake"
- Downregulates immune responses
- Blocking CTLA-4 enhances T-cell activation
- Often combined with PD-1 inhibitors for enhanced effect
Keytruda (Pembrolizumab)
Keytruda is a PD-1 inhibitor that has shown promising results in mesothelioma treatment.
How Keytruda Works
- Blocks PD-1 receptor on T-cells
- Prevents cancer cells from deactivating immune response
- Allows T-cells to recognize and attack mesothelioma cells
- Administered intravenously every 3-6 weeks
FDA Approval
Keytruda received accelerated FDA approval for mesothelioma in 2020:
- For patients with unresectable disease
- After progression on prior platinum-based chemotherapy
- Based on tumor response rates in clinical trials
Effectiveness
Clinical trial results show:
- Response rate: 14-20% of patients
- Disease control: 50-60% of patients
- Some patients achieve long-term disease control
- Better responses in tumors with higher PD-L1 expression
Opdivo (Nivolumab) + Yervoy (Ipilimumab)
The combination of Opdivo and Yervoy was the first immunotherapy regimen approved specifically for mesothelioma.
Dual Checkpoint Blockade
This combination targets two different checkpoint pathways:
- Opdivo: PD-1 inhibitor (like Keytruda)
- Yervoy: CTLA-4 inhibitor
- Combined effect: More powerful immune activation than either drug alone
FDA Approval
Approved in October 2020 for:
- Unresectable malignant pleural mesothelioma
- First-line treatment (no prior therapy required)
- Alternative to chemotherapy for eligible patients
Clinical Trial Results (CheckMate-743)
The pivotal trial showed significant benefits:
- Median overall survival: 18.1 months vs. 14.1 months with chemotherapy
- 2-year survival: 41% vs. 27%
- Benefit particularly strong for non-epithelioid cell types
- Durable responses in some patients
Treatment Schedule
- Opdivo every 2 weeks
- Yervoy every 6 weeks
- Yervoy typically given for 4 doses, then Opdivo alone
- Continues until disease progression or unacceptable toxicity
Who Can Benefit from Immunotherapy?
Not all mesothelioma patients are candidates for immunotherapy. Several factors influence eligibility.
Good Candidates
- Patients with unresectable disease
- Those who have progressed on chemotherapy
- Patients with good performance status
- Individuals without severe autoimmune conditions
- Non-epithelioid cell types (for Opdivo/Yervoy)
Predictive Biomarkers
Research is exploring factors that predict immunotherapy response:
- PD-L1 expression: Higher levels may predict better response to PD-1 inhibitors
- Tumor mutational burden: More mutations may increase likelihood of response
- Cell type: Non-epithelioid types may benefit more from combination therapy
- Immune cell infiltration: Tumors with more immune cells may respond better
Contraindications
Immunotherapy may not be appropriate for patients with:
- Severe autoimmune diseases (may flare with treatment)
- Recent organ transplantation
- Certain chronic infections
- Severe organ dysfunction
- History of severe immune-related adverse events
Side Effects of Immunotherapy
Immunotherapy side effects differ from chemotherapy and require different management approaches.
Common Side Effects
Generally mild and manageable:
- Fatigue
- Rash or itching
- Diarrhea
- Nausea
- Decreased appetite
- Joint pain
Immune-Related Adverse Events (irAEs)
More serious side effects occur when the immune system attacks healthy organs:
- Skin: Severe rash, vitiligo
- Gastrointestinal: Severe colitis
- Liver: Hepatitis (elevated liver enzymes)
- Lungs: Pneumonitis (inflammation)
- Endocrine: Thyroid problems, adrenal insufficiency
- Nervous system: Neuropathy, rare encephalitis
Managing Side Effects
- Early recognition and reporting are critical
- Corticosteroids often effective for irAEs
- Treatment may need to be held or stopped
- Endocrinology consultation for hormone issues
- Most side effects are reversible with proper management
When to Contact Your Doctor
Report immediately if you experience:
- Severe diarrhea (4+ episodes/day)
- Shortness of breath or cough
- Yellowing of skin or eyes
- Severe abdominal pain
- Extreme fatigue or weakness
- Signs of hormonal problems
Clinical Trials and Future Directions
Ongoing research continues to explore new immunotherapy combination approaches for mesothelioma. Patients interested in cutting-edge treatments should learn about the latest clinical trials in 2026.
Current Research Areas
- Combination therapies: Immunotherapy + chemotherapy, radiation, or surgery
- Novel checkpoint inhibitors: Targeting additional immune pathways
- Cancer vaccines: Stimulating immune response against tumor antigens
- CAR T-cell therapy: Engineering patient T-cells to attack mesothelioma
- Bi-specific antibodies: Simultaneously targeting cancer and immune cells
Notable Clinical Trials
- Pembrolizumab combinations: Various chemotherapy and targeted therapy pairings
- Durvalumab + tremelimumab: Another PD-1/CTLA-4 combination
- Neoadjuvant immunotherapy: Before surgery to improve outcomes
- Mesothelioma vaccines: WT1 and other antigen-targeting vaccines
Participating in Clinical Trials
Benefits of trial participation include:
- Access to cutting-edge treatments not yet widely available
- Close monitoring by research teams
- Contributing to research that helps future patients
- Potential for treatment when standard options are exhausted
Frequently Asked Questions About Immunotherapy
Is immunotherapy better than chemotherapy for mesothelioma?
Neither is universally "better"—they work differently. The Opdivo/Yervoy combination showed improved survival compared to chemotherapy in the CheckMate-743 trial (18.1 vs. 14.1 months median survival). Some patients respond exceptionally well to immunotherapy while others benefit more from chemotherapy. Treatment choice depends on individual factors.
How long does immunotherapy treatment last?
Immunotherapy is typically continued until disease progression or unacceptable side effects occur. Some patients remain on treatment for 1-2 years or longer. Unlike chemotherapy, which has set cycles, immunotherapy may provide continued benefit even after treatment ends due to immune memory.
What percentage of mesothelioma patients respond to immunotherapy?
Response rates vary by drug and patient population. For checkpoint inhibitors in previously treated patients, objective response rates are approximately 14-20%. Disease control (including stable disease) occurs in 50-60% of patients. Some patients achieve durable, long-term responses lasting years.
Can immunotherapy cure mesothelioma?
Currently, immunotherapy is not considered a cure for mesothelioma, though it can produce significant and durable responses in some patients. Complete responses (disappearance of all cancer) are rare but documented. Research continues to explore ways to improve cure rates.
Are there tests to predict if immunotherapy will work?
PD-L1 testing can help predict response to PD-1 inhibitors, though it's not a perfect predictor. Higher PD-L1 expression generally correlates with better response. Tumor mutational burden and other biomarkers are being studied. However, some patients without these markers still benefit from treatment.
Can immunotherapy be combined with other treatments?
Yes, clinical trials are actively exploring combinations including immunotherapy with chemotherapy, radiation therapy, and surgery. These combinations may enhance effectiveness. Your oncologist can discuss whether combination approaches are appropriate for your situation.
Explore Immunotherapy Options
Find out if immunotherapy might be right for you. Connect with mesothelioma specialists who can evaluate your eligibility for these advanced treatments.
Connect with Specialists